Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Fanny Erika Palumbo
Observed names:
Fanny E. Palumbo,
Fanny Palumbo
Institutions:
Vita-Salute San Raffaele University,
Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco"
Observed institutions:
Vita-Salute San Raffaele University,
University of Catania,
Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco"
ORCID:
0009-0006-4896-6666
Observed ORCID:
0009-0006-4896-6666
OpenAlex ID:
A5108327315
BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders
2026
·
Andrea Duminuco
, Paola De Luca
, et al.
·
Biomolecules
·
7
PDF
Real-World Outcomes in FLT3-ITD Mutated Acute Myeloid Leukemia: Impact of NPM1 Mutations and Allogeneic Transplantation in a Retrospective Unicentric Cohort
2025
·
Veronica Vecchio
, Andrea Duminuco
, et al.
·
Journal of Clinical Medicine
·
6
PDF
Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease
2024
·
Lucia Gozzo
, Salvatore Leotta
, et al.
·
Journal of Clinical Medicine
·
6
PDF
Length of Washout Period After Remission Does Not Influence Relapse Risk in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents Combined with Venetoclax
2025
·
Fanny Palumbo
, Andrea Duminuco
, et al.
·
Journal of Clinical Medicine
·
5
PDF
Impact of Pre‐Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents
2025
·
Giovanni Marconi
, Elisabetta Petracci
, et al.
·
American Journal of Hematology
·
5
PDF
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351
2025
·
Raffaele Palmieri
, Fabio Guolo
, et al.
·
Blood Advances
·
4
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia
2025
·
Calogero Vetro
, Bruno Garibaldi
, et al.
·
Blood Cancer Journal
·
4
PDF
Effectiveness of Gilteritinib Beyond Second‐Line Therapy in Relapsed/Refractory FLT3 ‐Mutated Acute Myeloid Leukemia: A Real‐World Multicenter Study of 171 Patients
2025
·
Matteo Molica
, Gema Miralles
, et al.
·
American Journal of Hematology
·
3
PDF
Extramedullary Acute Myeloid Leukemia: Evaluating Azacitidine—Venetoclax Combination Outcomes and the Role of Molecular Genetics and Bone Marrow Involvement
2025
·
Fanny E. Palumbo
, Calogero Vetro
, et al.
·
European Journal Of Haematology
·
3
Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational Study
2025
·
Ermelinda Longo
, Fanny Erika Palumbo
, et al.
·
Journal of Clinical Medicine
·
3
PDF
Three‐Hour Infusion of Methotrexate at 3 g/m 2 With or Without Intrathecal Chemotherapy Significantly Reduces CNS Relapses and Improves Survival in Patients With Large B‐Cell Lymphomas at Increased CNS Risk
2026
·
Andrés J. M. Ferreri
, Federico Erbella
, et al.
·
American Journal of Hematology
·
2
Benign purpuric cutaneous eruption in a young patient with AML treated with CPX-351
2025
·
Fanny Erika Palumbo
, Calogero Vetro
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
2
Endovascular management of pelvic congestion syndrome in males: A report of 2 cases
2026
·
Davide Giuseppe Castiglione
, Placido Di Grigoli
, et al.
·
Radiology Case Reports
·
1
NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort
2026
·
Calogero Vetro
, Irene Azzali
, et al.
·
Hematological Oncology
·
1
PDF
Vitamin K Antagonists (VKAs) and Novel Oral Anticoagulants (NOACs) Safety Comparison Based on Data from EudraVigilance Database
2025
·
Pier Paolo Olimpieri
, Fanny Erika Palumbo
, et al.
·
Hematology Reports
·
1
PDF
Second Primary Malignancies After Primary Gastric Lymphoma: Incidence, Risk Factors, and Clinical Implications
2026
·
Fanny Erika Palumbo
, Calogero Vetro
, et al.
·
Hemato
Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy
2026
·
Salvatore Perrone
, Andrea Corbingi
, et al.
·
Annals of Hematology
PDF
Safety of Drugs Used in Difficult-to-Treat Epileptic Syndromes: A Disproportionality Analysis Using the Eudravigilance Database
2025
·
Arianna Scala
, Teresa Angela Trunfio
, et al.
·
Pharmaceuticals
PDF
Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia
2025
·
Calogero Vetro
, Bruno Garibaldi
, et al.
·
Blood Cancer Journal
PDF
NPM1 and IDH1/2 mutations show limited prognostic impact in relapsed AML: Evidence from the avalon cohort
2025
·
Calogero Vetro
, Irene Azzali
, et al.
·
Blood
PDF
Show more works
View as search
Works count:
20
Citation count:
53
H-index:
5
I10-index:
Year
Topic
Type